project-idea

SCLC SubtypeTracker: Longitudinal Liquid Biopsy Subtype Monitor for Tarlatamab Patients

SCLC transcription factor subtype (ASCL1, NEUROD1, POU2F3) can be inferred from circulating chromatin in blood, and treatment with tarlatamab can drive subtype switching as a resistance mechanism — making serial liquid biopsy monitoring clinically actionable.

This research opens the door to a clinically impactful monitoring tool: a bioinformatics pipeline and report generator for serial liquid biopsy samples from SCLC patients on tarlatamab. The tool would process cell-free chromatin accessibility data from blood draws taken at regular treatment intervals and output a subtype classification report — including trend analysis showing whether the tumor's subtype composition is shifting over time.

Early signs of subtype switching (e.g., a patient transitioning from ASCL1-dominant to NEUROD1-dominant signal) could alert oncologists to emerging resistance weeks before clinical progression becomes apparent on imaging. The report could also flag when a patient's subtype might make them more or less likely to benefit from tarlatamab based on the predictive data from this paper.

Building this as an open-source pipeline with a simple report output (PDF or web dashboard) would make it accessible to academic medical centers running liquid biopsy studies on SCLC patients. It would also serve as a blueprint for subtype monitoring in other cancers where lineage plasticity drives resistance.

Who Is This For?

Clinical oncologists managing SCLC patients, translational researchers studying tarlatamab resistance, and bioinformaticians at academic cancer centers.

Skills & Tools Needed

Bioinformatics (chromatin accessibility analysis, ATAC-seq or cfChIP-seq processing)
Machine learning for subtype classification
Clinical report generation
Data visualization (longitudinal trend plots)
Understanding of SCLC molecular subtypes

Feasibility

low — The analysis method (circulating chromatin subtype inference) is cutting-edge and not yet standardized; requires wet-lab and computational expertise plus access to patient samples.

Inspired by: Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.